González CA, Malanco HLM, Sánchez ZMJ, Elizondo AS, Navarro ZJE, Rosillo RS

Idioma: Español
Referencias bibliográficas: 31
Paginas: 71-82
Archivo PDF: 127.26 Kb.

RESUMEN

Se ha observado una correlación positiva entre la presencia de resistencia a la insulina y niveles elevados de marcadores inflamatorios (entre ellos la proteína C reactiva de alta sensibilidad), ambos factores, tal como lo demuestran las evidencias, están asociados con un incremento en el riesgo para el desarrollo de diabetes mellitus tipo 2 y enfermedad cardiovascular. Se analiza y discute el papel de la inflamación y la resistencia a la insulina como marcadores para el desarrollo de la disfunción endotelial y ateroesclerosis y su interrelación con los procesos metabólicos (teoría del sobre-flujo y teoría portal). La aplicación de estos conocimientos permite tener una visión general sobre el desarrollo del “mecanismo antiinflamatorio de diversos medicamentos”.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Heeschen C, Dimmler S, Hamm CN. Soluble CD40 Ligand in Acute Coronary Syndromes. N Engl J Med 2003; 348: 1104-11.

2. Kuller LH, Eichnerje, Orchard TJ. The relation between serum albumin levels and Risk of Coronary Heart Disease in the multiple Risk Factor Intervention Trial. Am J Epidemiol 1991; 134: 1266-1277.

3. Ridker PM, Cushman M, Stampfer MJ. Inflammation, aspirin, and the Risk of cardiovascular disease in apparently health men. N Engl J Med 1997; 336: 973-979.

4. Weyer C, Yudkin J, Stehouwer CD et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002; 161: 233-242.

5. Palanioppan L, Carnet-hon MR, Wang Y et al. Predictors of the Incident Metabolic Syndrome in Adults. The Insulin Resistance Atherosclerosis Study (IRAS). 2004; 27(3): 788-793.

6. Frohlich M, Imhof A, Berg G et al. Association between Creactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-9.

7. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107(3): 363-9.

8. Yudkin JS, Kumari M. Humphries SE et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14.

9. Wu T, Dorn JP, Donahue RP et al. Associations of serum C-reactive protein with fasting insulin, glucose, and glucosylated hemoglobin: the third national health and nutrition examination survey, 1988-1999. Am J Epidemiol 2002; 155: 65-71.

10. Ridker PM, Hennekens CH, Buring JE, Rifai N. C Reactive Protein and other markers of inflammation in the prediction of Cardiovascular disease in Women. N Engl J Med 2000; 342: 836-843.

11. Horowitz GL; Beckwith BA. C. Reactive Protein in the Prediction of Cardiovascular Disease. N Engl J Med 2000; 343: 512-513.

12. James SK, Armstrong P, Barnathan E, Gusto - IV- ACS Investigators. Troponin and C Reactive protein have different relations to subsequent mortality and myocardial infarction after Acute coronary syndrome: a Gusto- IVSubstudy. J Am Coll Cardiol 2003; 40: 916-924.

13. Wanner C, Mezger T. C- Reactive protein, a Marker for allcause and cardiovascular Mortality in Haemodialysis Patients. Nephrol Dial Transplant 2002; 17Suppl 8: 29-32.

14. Pearson TA, Mensah GA, Alexander RN. Markers of inflammation and Cardiovascular Disease: Application to clinical and public Health Practice: A statement for Healthcare professionals from the Centers for Disease Control and prevention and the American Heart Association. Circulation 2003; 107: 999-511.

15. Assmann F, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of Follow-Up at 8 years. Eur Heart J 1998; 19 (Suppl A): 2-1.

16. Karel W. The pathogenesis of Coronary Disease And Acute Coronary Syndromes. In: Fuster V, Ross A, Topol E (Eds), Lippicott Raven, New Cork, 1996: 1591.

17. Dalager-Pedersons, Pederson EM, Ringaard S, Coronary Artery Disease: Plaque vulnerability, Disruption and thrombosis. In: Fuster V (ed). The Vulnerable atherosclerotic plaque. Futura Publishing Inc. New York 1999: 1-23.

18. Falk E, Shak PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.

19. Ziada KM, Vince DG, Kissen SE. Arterial Remodeling and coronary artery disease: The concept of “dilated” versus “obstructive” coronary atherosclerosis. J Am Coll Cardiol 2001; 38: 297-306.

20. Glagov S, Weiserberg E, Zarins CK. Compensatory enlargement of human atherosclerotic coronary arteries. Engl J Med 1987; 316: 1371-5.

21. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340: 115-126.

22. Devavaj S, Rosenson R, Jialal I. Metabolic Syndrome: an appraisal of the pro-inflammatory and procoagulant status. 2004; 33(2): 184.

23. González A, Sánchez ZM, Elizondo AS, Malanco HM. Inflamación y Resistencia a la Insulina, su papel en el desarrollo del Síndrome Metabólico. Annual Review del Colegio de Medicina Interna de México. Edit. Intersistemas 1ª. Edición 2005: 177-191.

24. Valen G, Yan Z, Hanson GK. Nuclear Factor Kappa-B and the Heart. J Am Coll Cardiol 2001; 38: 307-314.

25. Calabró P, Willerson JT, Yeh ETH. Inflammatory Cytokines Stimulated C. Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells. Circulation 2003; 108: 1930-1932.

26. Kintscher U. Vascular Protection in diabetes: a pharmacological view of Angiotensina II Type 1 receptor blochens. Acta Diabetol 2005; 42: S26-S32.

27. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823.

28. Guenther B, Markku Laakso MD. Lipids and glucose in Type 2 Diabetes. Diabetes Care 2004; 27: 2253-2259.

29. Danesh JL, Whuincup P, Walher M. Low grade inflammation and coronary Heart Disease: Prospective Study and adapted meta analyses. BMJ 2000; 321: 199-206.

30. González A. Consenso Mexicano de Resistencia a la Insulina y Síndrome Metabólico. Rev Mex Cardiol 1999; 10(1): 3-18.

31. González A. Consenso Mexicano sobre el Tratamiento Integral del Síndrome Metabólico Medicina Interna Méx. 2002; 18(1): 12-41.